Publications

Financial Report 2021

After five years in operation, GARDP has formed numerous partnerships with industry, academia and research institutions in support of its clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis (a bloodstream infection), sexually transmitted infections and serious bacterial infections. These collaborations span the drug development lifecycle and include screening chemical libraries for antibacterial activity, assessing the viability of potential antibiotic candidates, and the completion of three clinical trials.